21 May 2013
Keywords: life, study, cozaar, landmark, treatment, hypertension, merck
Article | 25 March 2002
Merck & Co's angiotensin II receptor antagonist Cozaar (losartan)should now become first-line therapy in the management of hypertension,
ahead of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 March 2002
20 May 2013
© 2013 thepharmaletter.com